Related Experiment Videos
Coronary artery disease risk factor management in the hypertensive patient
Insights
Managing hypertension involves more than just lowering blood pressure. Addressing other risk factors like high cholesterol and lifestyle choices, alongside selecting antihypertensive drugs with favorable metabolic profiles, is crucial for reducing coronary artery disease (CAD) risk.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Coronary artery disease (CAD) risk is influenced by multiple factors beyond elevated blood pressure.
- Hypertension management requires a comprehensive approach considering associated metabolic and lifestyle risks.
Purpose of the Study:
- To evaluate the impact of various risk factors on coronary artery disease (CAD) in hypertensive patients.
- To assess the role of antihypertensive drug selection based on metabolic effects in managing CAD risk.
Main Methods:
- Review of current understanding of CAD risk factors in hypertensive patients.
- Analysis of metabolic profiles associated with different classes of antihypertensive medications.
Main Results:
- Elevated blood pressure, hypercholesterolemia, hyperglycemia, obesity, smoking, and sedentary lifestyle significantly increase CAD risk.
- Diuretics and beta-blockers may have adverse metabolic effects, while selective alpha-1 inhibitors show potential benefits.
- The long-term impact of drug-induced metabolic changes on patient prognosis requires further investigation.
Conclusions:
- Optimal CAD risk reduction in hypertensive patients necessitates controlling blood pressure and other risk factors.
- Antihypertensive drug choice should consider metabolic effects to avoid exacerbating CAD risk.
- Prioritizing medications with neutral or beneficial metabolic profiles is advisable when clinically appropriate.
Abstract:
Recent advances in understanding the relation of risk factors to coronary artery disease (CAD) have initiated a change in the approach to managing the hypertensive patient. Reduction of elevated blood pressure still remains a major therapeutic priority. However, the risk of cardiovascular morbidity is also related to hypercholesterolemia, hyperuricemia, hyperglycemia, hyperfibrinogenemia and obesity; all aggravate the risk of CAD in the patient with high blood pressure. Life-style is also important: cigarette smoking, high alcohol consumption and lack of physical exercise all predispose to precocious atheromatous CAD. Thus, the most favorable prognosis in terms of reducing CAD risk is accomplished by reducing elevated systemic arterial pressure while simultaneously improving all other risk factors. The method by which blood pressure is lowered is an important consideration. The ancillary metabolic activities of antihypertensive drugs now available differ widely. Diuretics and beta blockers, for example, have potentially adverse metabolic effects, whereas agents such as selective alpha 1-adrenoceptor inhibitors appear to beneficially affect several metabolic cofactors influencing the CAD risk profile. The impact of such drug-induced metabolic changes on overall prognosis of the hypertensive patient remains to be clarified. In the absence of other contraindications, however, it is sensible to use drugs that do not increase the metabolic predilection to precocious CAD.